Sudhir Agrawal

Summary

Publications

  1. ncbi Antisense therapeutics
    S Agrawal
    Hybridon Inc, Cambridge, MA 02139, USA
    Curr Opin Chem Biol 2:519-28. 1998
  2. ncbi Antisense and/or immunostimulatory oligonucleotide therapeutics
    S Agrawal
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Curr Cancer Drug Targets 1:197-209. 2001
  3. ncbi GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts
    Sudhir Agrawal
    Hybridon, Inc, Cambridge, MA 02139, USA
    Int J Oncol 21:65-72. 2002
  4. ncbi Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA
    Sudhir Agrawal
    Hybridon, Inc, Cambridge, Massuchusetts 02139, USA
    Ann N Y Acad Sci 1002:30-42. 2003
  5. ncbi Role of Toll-like receptors in antisense and siRNA [corrected]
    Sudhir Agrawal
    Hybridon, Inc, 345 Vassar Street, Cambridge, Massachusetts 02139, USA
    Nat Biotechnol 22:1533-7. 2004
  6. ncbi Medicinal chemistry and therapeutic potential of CpG DNA
    Sudhir Agrawal
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02137, USA
    Trends Mol Med 8:114-21. 2002
  7. ncbi Antisense therapeutics: is it as simple as complementary base recognition?
    S Agrawal
    Hybridon, 155 Fortune Boulevard, Milford, MA 01757, USA
    Mol Med Today 6:72-81. 2000
  8. ncbi Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides
    S Agrawal
    Hybridon, Inc, Milford, MA 01757, USA
    Biochim Biophys Acta 1489:53-68. 1999
  9. ncbi Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides
    S Agrawal
    Hybridon, Inc, Cambridge, MA 02139, USA
    Int J Oncol 18:1061-9. 2001
  10. ncbi Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 102:6925-30. 2005

Collaborators

Detail Information

Publications81

  1. ncbi Antisense therapeutics
    S Agrawal
    Hybridon Inc, Cambridge, MA 02139, USA
    Curr Opin Chem Biol 2:519-28. 1998
    ..Questions regarding the specificity of action and side effects of antisense phosphorothioate oligonucleotides have arisen simultaneously...
  2. ncbi Antisense and/or immunostimulatory oligonucleotide therapeutics
    S Agrawal
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Curr Cancer Drug Targets 1:197-209. 2001
    ....
  3. ncbi GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts
    Sudhir Agrawal
    Hybridon, Inc, Cambridge, MA 02139, USA
    Int J Oncol 21:65-72. 2002
    ..These results suggest that the use of irinotecan in combination with GEM 231 may increase the therapeutic index of irinotecan in cancer patients...
  4. ncbi Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA
    Sudhir Agrawal
    Hybridon, Inc, Cambridge, Massuchusetts 02139, USA
    Ann N Y Acad Sci 1002:30-42. 2003
    ....
  5. ncbi Role of Toll-like receptors in antisense and siRNA [corrected]
    Sudhir Agrawal
    Hybridon, Inc, 345 Vassar Street, Cambridge, Massachusetts 02139, USA
    Nat Biotechnol 22:1533-7. 2004
    ..Do antisense and siRNA agents work as ligands for Toll-like receptors (TLRs), a family of pathogen-associated, molecular pattern recognition receptors?..
  6. ncbi Medicinal chemistry and therapeutic potential of CpG DNA
    Sudhir Agrawal
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02137, USA
    Trends Mol Med 8:114-21. 2002
    ..This article reviews recent progress in understanding the effects of CpG DNA, the medicinal chemistry of CpG DNA, and its possible therapeutic applications...
  7. ncbi Antisense therapeutics: is it as simple as complementary base recognition?
    S Agrawal
    Hybridon, 155 Fortune Boulevard, Milford, MA 01757, USA
    Mol Med Today 6:72-81. 2000
    ..Here, we discuss different mechanisms of action of oligonucleotides and the possible ways of minimizing non-antisense-related [corrected] effects to improve their specificity...
  8. ncbi Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides
    S Agrawal
    Hybridon, Inc, Milford, MA 01757, USA
    Biochim Biophys Acta 1489:53-68. 1999
    ....
  9. ncbi Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides
    S Agrawal
    Hybridon, Inc, Cambridge, MA 02139, USA
    Int J Oncol 18:1061-9. 2001
    ..The use of chemically modified oligonucleotides together with irinotecan may increase the therapeutic index of irinotecan in cancer patients and continued development of such agents should be considered...
  10. ncbi Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 102:6925-30. 2005
    ..These results suggest that IMOs induce strong and rapid immunostimulation and that the CpR dinucleotide is recognized by TLR9, leading to immune-cell activation and cytokine secretion in vitro and in vivo...
  11. ncbi Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Nucleic Acids Res 31:2393-400. 2003
    ....
  12. ncbi Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Bioorg Med Chem 11:459-64. 2003
    ..It was found that 'GXCGTT' motif has an intermediate immunostimulatory activity between those of 'GACGTT' and 'GTCGTT' in the mouse cells...
  13. ncbi A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 100:14303-8. 2003
    ....
  14. ncbi Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice
    Fu Gang Zhu
    Idera Pharmaceuticals, Inc, Cambridge, Mass, USA
    J Allergy Clin Immunol 120:631-7. 2007
    ..Agonists of Toll-like receptor 9 have been shown to induce potent T(H)1-type immune responses and prevent and reverse ovalbumin-induced T(H)2-dominant allergic asthma in mice...
  15. ncbi Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies
    Tao Lan
    Idera Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    J Med Chem 52:6871-9. 2009
    ..In conclusion, we have designed and synthesized novel SIMRA compounds that selectively act as agonists of TLR7...
  16. ncbi Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs
    Dong Yu
    Idera Pharmaceuticals, Inc, 167 Sidney Street, Cambridge, Massachusetts 02139, USA
    J Med Chem 50:6411-8. 2007
    ....
  17. ncbi Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs
    Daqing Wang
    Hybridon, Inc, Cambridge, MA 02139, USA
    Int J Oncol 24:901-8. 2004
    ..IMO treatment resulted in the development of tumor-specific memory immune responses. No treatment-related toxicity was observed in mice at the doses and treatment schedules studied...
  18. ncbi Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications
    Mallikarjuna Reddy Putta
    Idera Pharmaceuticals, Inc. 345 Vassar Street, Cambridge, MA 02139, USA
    Nucleic Acids Res 34:3231-8. 2006
    ..These are the first studies elucidating the role of N3-position of cytosine and N1-position of guanine in a CpG motif for TLR9 activation and immune stimulation...
  19. ncbi CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents
    Lakshmi Bhagat
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 300:853-61. 2003
    ..Short-immunomer also inhibits growth of MCF-7 human tumor xenograft in nude mice. This is the first report of activity with such short DNA sequences and also of sequences lacking hexameric motifs proposed in earlier studies...
  20. ncbi Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, Massachusetts 02139, USA
    J Med Chem 45:4540-8. 2002
    ..Substitution of deoxyribonucleosides with a C3 or C4 alkyl-linker was found to be optimal for potentiating immunostimulatory activity...
  21. ncbi Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice
    Yukui Li
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139-4818, United States
    Int Immunopharmacol 5:981-91. 2005
    ..2 microg. These data demonstrate that IMOs enhance the immunogenicity of HBsAg through potent Th1 immune responses, which may allow lower doses of antigen in vaccination...
  22. ncbi Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9
    Dong Yu
    Idera Pharmaceuticals, Inc, 167 Sidney Street, Cambridge, MA 02139, USA
    J Med Chem 52:5108-14. 2009
    ..These types of modifications are commonly employed in antisense sequences and thereby may affect the intended mechanism of action...
  23. ncbi Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction
    Dong Yu
    Idera Pharmaceuticals, 167 Sidney Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 52:4320-5. 2008
    ..Taken together, the present results suggest that oligonucleotide-based agonists of TLR9 that form intermolecular duplexes induce potent immune responses in vivo...
  24. ncbi Secondary structures in CpG oligonucleotides affect immunostimulatory activity
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139-4818, USA
    Biochem Biophys Res Commun 306:948-53. 2003
    ..These results may also provide insights to place CpG motifs appropriately in DNA vaccines to induce additional Th1 type responses...
  25. ncbi Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8
    Tao Lan
    Idera Pharmaceuticals, Inc, 167 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 104:13750-5. 2007
    ..This is a comprehensive study of RNA-based compounds containing structures and synthetic stimulatory motifs in mouse, monkey, and human systems without using lipid carriers...
  26. ncbi Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice
    Fu-Gang Zhu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Int Immunopharmacol 4:851-62. 2004
    ..These data demonstrate that IMOs prevent antigen-induced Th2 immune responses when co-administered to mice during OVA sensitization and that IMOs reverse established allergic responses induced by OVA...
  27. ncbi Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8
    Daqing Wang
    Idera Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    Mol Cancer Ther 9:1788-97. 2010
    ..CL25 pulmonary metastasis model. These studies show that the dual TLR7/8 agonist induced Th1-type immune responses and potent antitumor activity in mice via TLR7 and through the MyD88-dependent pathway...
  28. ncbi Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity
    Daqing Wang
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Vaccine 23:2614-22. 2005
    ..IMOs may prove to be effective oral adjuvants, able to promote strong systemic and mucosal immune responses to oral vaccines and antigens for therapeutic and prophylactic applications...
  29. ncbi 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Nucleic Acids Res 30:4460-9. 2002
    ..These results suggest that immunomers have several advantages over conventional linear CpG DNAs for immunomodulatory activity studies...
  30. ncbi Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, Massachusetts 02139, USA
    Bioconjug Chem 13:966-74. 2002
    ..These results suggest that for optimal immunostimulatory activity, ligands should not be attached at the 5'-end of the CpG DNA...
  31. ncbi Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists
    Ekambar R Kandimalla
    Idera Pharmaceuticals, Inc, Cambridge, MA 02139, United States
    Cell Immunol 270:126-34. 2011
    ..In conclusion, we have designed and synthesized novel ORNs with varying sequence compositions and chemical modifications, which selectively act as agonists of TLR8 or dual agonists of TLR7 and TLR8...
  32. ncbi Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 297:83-90. 2002
    ..PO-immunomers activated NF-kappa B and induced cytokine secretion in J774 cell cultures. In addition, PO-immunomers showed antitumor activity in nude mice bearing human breast (MCF-7) and prostate (DU145) cancer xenografts...
  33. ncbi Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8
    Tao Lan
    Idera Pharmaceuticals, Inc, 167 Sidney Street, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 386:443-8. 2009
    ..These results suggest that secondary structures in ORN provide nuclease stability and lead to stimulation of immune responses through TLR8 as well as TLR7 depending on the presence of specific nucleotide motifs...
  34. ncbi Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9
    Daqing Wang
    Idera Pharmaceuticals, Inc, 167 Sidney Street, Cambridge, Massachusetts 02139, USA
    J Med Chem 52:551-8. 2009
    ..Antagonists may be suitable candidates for treating inflammatory and autoimmune diseases where inappropriate or uncontrolled TLR activation has been implicated...
  35. ncbi Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity
    Lakshmi Bhagat
    Idera Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, United States
    J Med Chem 54:3027-36. 2011
    ..These results suggest that GSOs are novel agents for gene silencing that can be delivered systemically with broader applicability...
  36. ncbi Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity
    Mallikarjuna Reddy Putta
    Idera Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    Bioconjug Chem 21:39-45. 2010
    ....
  37. ncbi Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8
    Tao Lan
    Idera Pharmaceuticals, Inc, 167 Sidney Street, Cambridge, MA 02139, United States
    Bioorg Med Chem Lett 19:2044-7. 2009
    ..In human PBMC and pDC assays, SIMRA compounds containing arabinonucleotides induced Th1-type cytokine profiles. These results suggest that SIMRA compounds containing arabinonucleotides act as agonists of TLR7 and TLR8...
  38. ncbi Towards optimal design of second-generation immunomodulatory oligonucleotides
    Ekambar R Kandimalla
    Hybridon Inc, Cambridge, MA 02139, USA
    Curr Opin Mol Ther 4:122-9. 2002
    ..In addition, we describe the design of second-generation CpG DNA agents, and clinical applications of first-generation agents...
  39. ncbi Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells
    Yan-Ping Cong
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Biochem Biophys Res Commun 310:1133-9. 2003
    ..Further modifications of the hairpin duplex region with a mixture of oligodeoxynucleotides and oligo-2'-O-methylribonucleotides in a heteroduplex formation permitted activation of both human B cells and pDCs...
  40. ncbi Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages
    Dong Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Nucleic Acids Res 30:1613-9. 2002
    ..These results suggest that site-specific incorporation of 3'-deoxynucleotides in CpG DNA modulates immunostimulatory properties...
  41. ncbi Chemistry of CpG DNA
    Ekambar R Kandimalla
    Hybridon, Inc, Cambridge, Massachusetts, USA
    Curr Protoc Nucleic Acid Chem . 2003
    ..This unit discusses the receptors that recognize CpG motifs and important aspects of the sequence context of CpG motifs to the end of understanding and designing CpG DNA for therapeutic purposes...
  42. ncbi Hybridization-based fluorescence assay allows quantitation of single-stranded oligodeoxynucleotides in low nanomolar range
    Ekambar R Kandimalla
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Anal Biochem 328:93-5. 2004
  43. ncbi Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages
    D Yu
    Hybridon Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Bioorg Med Chem 9:2803-8. 2001
    ..These results have significance in understanding CpG oligonucleotide-receptor interactions and the development of potent immunomodulatory agents...
  44. ncbi Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships
    E R Kandimalla
    Hybridon, Inc, Cambridge, MA 02139, USA
    Bioorg Med Chem 9:807-13. 2001
    ..These studies suggest that it is possible to develop YpG- and CpR-motifs as an alternative to CpG-motifs in PS-oligos for immunostimulatory studies...
  45. ncbi Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases
    D Yu
    Hybridon, Inc, 345 Vassar Street, Cambridge, MA 02139, USA
    Bioorg Med Chem Lett 11:2263-7. 2001
    ....
  46. ncbi Synthetic agonists of Toll-like receptors 7, 8 and 9
    S Agrawal
    Idera Pharmaceuticals, 167 Sidney Street, Cambridge, MA 02139, USA
    Biochem Soc Trans 35:1461-7. 2007
    ..A second candidate, IMO-2125, is also a TLR9 agonist that has been shown to induce high and sustained levels of IFN (interferon) in non-human primates and is being evaluated in HepC-infected human subjects...
  47. ncbi Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms
    Hui Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA
    Mol Med 8:185-99. 2002
    ..This study should provide a basis for future development of anti-MDM2 antisense oligonucleotides as cancer therapeutic agents used alone or in combination with conventional chemotherapeutics...
  48. ncbi Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9
    Hui Wang
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294-0019, USA
    Mol Cancer Ther 5:1585-92. 2006
    ..The present study provides a rationale for developing the immunomodulatory oligonucleotide for lung cancer therapy...
  49. ncbi Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy
    Hui Wang
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Boulevard, 113 Volker Hall, 35294, USA
    Mol Cancer Ther 5:2106-14. 2006
    ..Based on the present results, we believe that the IMO is a good candidate for clinical development for breast cancer therapy used either alone or in combination with conventional cancer therapeutic agents...
  50. ncbi Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms
    Hui Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA
    Prostate 54:194-205. 2003
    ....
  51. ncbi TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
    Vincenzo Damiano
    Departments of Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Proc Natl Acad Sci U S A 104:12468-73. 2007
    ....
  52. ncbi Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
    Radka Stoyanova
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:1151-60. 2007
    ..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
  53. ncbi Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms
    Hui Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Int J Oncol 20:745-52. 2002
    ..These results suggest that oligonucleotides have a role in irinotecan metabolism and action, providing a basis for future development of antisense oligonucleotides as a sensitizer for irinotecan-based therapy...
  54. ncbi Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors
    Vincenzo Damiano
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Istituto di Anatomia Patologica, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, , Via S. Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 12:577-83. 2006
    ..Moreover, this therapeutic strategy could be translated in patients affected by colorectal cancer...
  55. ncbi Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640
    Eric C LaCasse
    Aegera Therapeutics Inc, Montreal, Quebec, Canada H3E 1A8
    Ann N Y Acad Sci 1058:215-34. 2005
    ....
  56. ncbi Novel MDM2 p53-independent functions identified through RNA silencing technologies
    Zhuo Zhang
    Department of Pharmacology and Toxicology and Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Ann N Y Acad Sci 1058:205-14. 2005
    ....
  57. ncbi Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
    Hui Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA
    Int J Oncol 21:73-80. 2002
    ..These results suggest that GEM231 have a role in irinotecan metabolism and its antitumor activity, providing a basis for future development of this oligonucleotide as a chemosensitizer for irinotecan-based therapy...
  58. ncbi Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme
    Gautam Prasad
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 35294-0019, USA
    Anticancer Res 22:107-16. 2002
    ..In conclusion, inhibiting MDM2 expression could be a novel pharmacological approach to glioblastoma therapy...
  59. ncbi Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models
    Zhuo Zhang
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA
    Clin Cancer Res 10:1263-73. 2004
    ....
  60. ncbi Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, , Naples, Italy
    Clin Cancer Res 10:4858-64. 2004
    ....
  61. ncbi Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation
    Yee Sook Cho
    Cellular Biochemistry Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892 1750, USA
    Clin Cancer Res 8:607-14. 2002
    ....
  62. ncbi Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms
    Ruiwen Zhang
    Departments of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA
    Curr Cancer Drug Targets 5:43-9. 2005
    ..These results provide a basis for clinical evaluation of antisense anti-MDM2 oligonucleotides as chemosensitizers and radiosensitizers. In addition, the MBO has been successfully used to identify novel functions of MDM2...
  63. ncbi Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 68:599-609. 2008
    ..In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells...
  64. ncbi Thermal stress-induced HSP70 mediates protection against intrapancreatic trypsinogen activation and acute pancreatitis in rats
    Lakshmi Bhagat
    Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 122:156-65. 2002
    ..The worsening of pancreatitis, which occurs when non-thermally stressed animals are given AS-HSP70 before cerulein, suggests that cerulein-induced HSP70 expression in nontreated animals acts to limit the severity of pancreatitis...
  65. ncbi Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics
    Dan C McManus
    Aegera Oncology Inc, University of Ottawa and Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada K1H 8L1
    Oncogene 23:8105-17. 2004
    ....
  66. ncbi Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis
    Eric C LaCasse
    Aegera Therapeutics, Inc, Montreal, Quebec, Canada
    Clin Cancer Res 12:5231-41. 2006
    ..AEG35156 is presently under clinical assessment in multiple phase I trials in cancer patients as a single agent and in combination with docetaxel in solid tumors or cytarabine/idarubicin in leukemia...
  67. ncbi Immune modulatory oligonucleotides in the prevention and treatment of OVA-induced eustachian tube dysfunction in rats
    Deidra A Blanks
    Department of Otolaryngology Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Otolaryngol Head Neck Surg 137:321-6. 2007
    ..Otitis media with effusion (OME) is often associated with allergies. Immune modulatory oligonucleotides (IMO) mediate allergic inflammation and may therefore be efficacious in the treatment of airway inflammation...
  68. ncbi CRIPTO-1: a novel target for therapeutic intervention in human carcinoma
    Nicola Normanno
    Department of Experimental Oncology, INT Fondazione Pascale, Via Mariano Semmola, I 80131 Naples, Italy
    Int J Oncol 25:1013-20. 2004
    ..Taken together, these data strongly suggest that CR-1 might represent a novel target for therapeutic intervention in different carcinoma types...
  69. ncbi Impact of site-specific nucleobase deletions on the arthritogenicity of DNA
    Jan L Bjersing
    Department of Rheumatology and Inflammation Research, University of Goteborg, Goteborg, Sweden
    Inflammation 28:159-68. 2004
    ..This study indicates that specific structural elements within the ODN sequence but outside the CpG motif, modulate the immunostimulatory properties of CpG ODNs...
  70. ncbi Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma
    Devendra K Agrawal
    Medical Microbiology and Immunology and Biomedical Sciences, Center for Allergy, Asthma and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
    Int Immunopharmacol 4:127-38. 2004
    ..These data suggest that the treatment with these novel IMOs prevents OVA-induced allergic airway inflammation and AHR in asthma in the mouse and may provide a useful agent in the treatment of human asthma...
  71. ncbi Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms
    Hui Wang
    Departments of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, Alabama 35294-0019, USA
    Ann N Y Acad Sci 1002:217-35. 2003
    ..These results provide a basis for clinical evaluation of antisense anti-MDM2 oligonucleotides as chemosensitizer and radiosensitizer...
  72. ncbi Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:336-43. 2004
    ..CONCLUSION: AS sensitizes cells to AD, RT, and AD+RT and shows promise in the treatment of the full range of patients with prostate cancer. AS has the potential to sensitize the primary tumor to AD+RT and metastasis to AD...
  73. ncbi Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 60:187-96. 2004
    ..Antisense MDM2 has broad potential as a therapeutic agent to sensitize prostate cancer cells to AD therapy by enhancing apoptotic cell death...
  74. ncbi Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway
    Zhuo Zhang
    Department of Pharmacology and Toxicology and Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Oncogene 24:7238-47. 2005
    ..More knowledge about the MDM2-E2F1 interaction may be helpful in developing novel anticancer therapies...
  75. ncbi Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice
    Daria Trabattoni
    Chair of Immunology, DISP LITA Vialba, Via GB Grassi 74, 20157 Milano, Italy
    Vaccine 24:1470-7. 2006
    ..The immune enhancing effects of HYB2055 adjuvant were dose-dependent. These findings warrant clinical evaluation of the HIV-1 immunogen/HYB2055 candidate as a therapeutic vaccine for HIV-1 infected patients...
  76. ncbi A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors
    Sanjay Goel
    Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 9:4069-76. 2003
    ..Alternative dosing schedules should include intermittent administration to minimize cumulative toxicity. Additional studies using intermittent continuous infusion schedules of GEM231 are warranted...
  77. ncbi The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction
    Charles S Ebert
    Department of Otolaryngology Head and Neck Surgery, CB 7070, G0412 Neurosciences Hospital, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7070, United States
    Int J Pediatr Otorhinolaryngol 70:2019-26. 2006
    ..To evaluate the potential role of immunomodulatory oligonucleotides (IMO) in the prevention of OVA-induced Eustachian tube dysfunction (ETD) in a rat model...
  78. ncbi Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy
    Zhuo Zhang
    Department of Pharmacology and Toxicology and Comprehensive Cancer Center, University of Alabama at Birmingham, VH 113, 1670 University Boulevard, Birmingham, AL 35294, USA
    Proc Natl Acad Sci U S A 100:11636-41. 2003
    ..MDM2 inhibitors such as second-generation antisense oligonucleotides have a broad spectrum of antitumor activities in human cancers regardless of p53 status, providing novel approaches to therapy of human prostate cancer...
  79. ncbi Was induction of HIV-1 through TLR9?
    Sudhir Agrawal
    J Immunol 171:1621; author reply 1621-2. 2003
  80. ncbi Immune modulatory oligonucleotides in prevention of nasal allergen-induced Eustachian tube dysfunction in rats
    Charles S Ebert
    Department of Otolaryngology Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Otolaryngol Head Neck Surg 137:250-5. 2007
    ..Develop a model of nasal allergen-induced Eustachian tube dysfunction (ETD) in a rat and investigate the role of immune modulatory oligonucleotides (IMOs) in the prevention of nasal allergen-induced ETD...
  81. ncbi Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis
    Weiwen Jiang
    Division of Rheumatology and Department of Immunology, Duke University Medical Center, Durham, NC, USA
    Biochem Biophys Res Commun 318:60-6. 2004
    ..The levels of corticosterone induced by HYB2048 were also significantly lower than those induced by LPS. This pattern of activation could distinguish CpG DNA from LPS in its effects on the immune system...